{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":4,"sponsored":0,"items":[{"id":"n_7xqtaos47duworry4msa","seq":1635537,"kind":"article","title":"Otsuka (OTCMKTS:OTSKY) vs. Inhibikase Therapeutics (NASDAQ:IKT) Financial Analysis","url":"https://www.themarketsdaily.com/2026/10/04/otsuka-otcmktsotsky-vs-inhibikase-therapeutics-nasdaqikt-financial-analysis.html","published":"2026-10-04T07:50:42Z","seen":"2026-10-04T07:50:42Z","lang":"en","source":{"id":"themarketsdaily.com","name":"themarketsdaily.com","domain":"themarketsdaily.com"},"via":"gdelt-gkg-english","topics":["economy","education","health","business"],"authors":["Kim Johansen"],"entities":[{"id":"Q19001460","name":"Koichi Otsuka","type":"org"}],"story":"st_7xqtaos47duworry4msa","category":"economy-business","category_p":0.54,"sentiment":"neutral","tone":0.23,"political":0.11},{"id":"n_s4rl47lrj56e6idejrta","seq":1574916,"kind":"article","title":"Head to Head Review: Otsuka (OTCMKTS:OTSKY) versus Dr. Reddy's Laboratories (NYSE:RDY)","url":"https://www.themarketsdaily.com/2026/10/03/head-to-head-review-otsuka-otcmktsotsky-versus-dr-reddys-laboratories-nyserdy.html","published":"2026-10-03T18:52:42Z","seen":"2026-10-03T18:52:42Z","lang":"en","source":{"id":"themarketsdaily.com","name":"themarketsdaily.com","domain":"themarketsdaily.com"},"via":"gdelt-gkg-english","topics":["economy","health","business","agriculture"],"authors":["Sarita Garza"],"entities":[{"id":"Q19001460","name":"Koichi Otsuka","type":"org"},{"id":"Q908961","name":"Dr. Reddy's Laboratories","type":"org"}],"story":"st_s4rl47lrj56e6idejrta","category":"science-technology","category_p":0.29,"category2":"health","sentiment":"neutral","tone":0.18,"political":0.05},{"id":"n_afq7t4al5jwr2gybe6dq","seq":1247519,"kind":"article","title":"Otsuka's Taiho Starts US Filing for Zipalertinib as a First-Line Lung Cancer Combination","url":"https://tokyobrief.com/articles/otsuka-taiho-zipalertinib-fda-rtor-first-line-lung-cancer","summary":"Otsuka says Taiho has begun an FDA application for zipalertinib with chemotherapy in untreated EGFR exon 20 lung cancer, with the filing due to finish by end-2026 and no change to the company's current-year forecast.","published":"2026-10-02T01:37:49Z","seen":"2026-10-02T01:43:07Z","lang":"ja","country":"JP","source":{"id":"kite-tokyobrief-com-a5667e","name":"tokyobrief.com","domain":"tokyobrief.com","outlet":{"wikidata":"Q141513445","name":"Tokyo Brief","type":"other","designations":["newsletter"]}},"via":"kite-tokyobrief-com-a5667e","entities":[{"id":"Q19001460","name":"Koichi Otsuka","type":"org"},{"id":"Q131418163","name":"Zipalertinib","type":"other"}],"image":"https://tokyobrief.com/media/tokyo-brief-2026-10-02-otsuka-taiho-zipalertinib-fda-rtor-first-line-lung-cancer-2c4eeaa94af7f674a848925bfd34c9b63071a7505a63f2a1ef4f2c07b6ae615d.png?v=card","story":"st_afq7t4al5jwr2gybe6dq","category":"health","category_p":0.44,"sentiment":"neutral","tone":0.16,"political":0.2},{"id":"n_rvssoopdam2wgnrfob5a","seq":531053,"kind":"article","title":"오츠카-아이오니스 ALS 치료제 3상 임상결과 양호","title_en":"Otsuka-Aionis ALS treatment drug phase 3 clinical results good","url":"https://www.bosa.co.kr/news/articleView.html?idxno=3012823","summary":"신속승인 위해 전세계 규제당국과 협의 예정[의학신문·일간보사=정우용 기자] 일본 오츠카제약과 미국 아이오니스 파마슈티컬스는 공동으로 개발 중인 유전성 근위축성 측삭경화증(ALS) 치료물질 \\'울레프너센\\'(ulefnersen)이 후기 임상시험에서 1차 평가항목을 달성했다고 발표했다.안티센스 올리고뉴클레오티드(ASO) 치료제 울레프너센은 운동을 제어하는 신경세포에 손상을 미치는 유전성 ALS의 일종인 FUS 유전자 변이에 의한 근위축성 측삭경화증(FUS-ALS)과 관련한 FUS 단백질의 생산을 억제하도록 설계됐다.아이오니스는 FUS-AL","published":"2026-09-28T21:00:00Z","seen":"2026-09-28T22:04:51Z","lang":"ko","source":{"id":"kite-bosa-co-kr-134b8e","name":"bosa.co.kr","domain":"bosa.co.kr","outlet":{"wikidata":"Q20445876","name":"Q20445876","type":"newspaper","country":"KR","designations":["newspaper"]}},"via":"kite-bosa-co-kr-134b8e","topics":["medicine","해외"],"authors":["정우용 기자"],"entities":[{"id":"Q19001460","name":"Koichi Otsuka","type":"org"},{"id":"Q206901","name":"amyotrophic lateral sclerosis","type":"other"}],"story":"st_rvssoopdam2wgnrfob5a","category":"health","category_p":0.49,"sentiment":"positive","tone":0.38,"political":0.04}]}